Survival Outcomes in Advanced Melanoma Treatment
Summary
The past decade has witnessed a transformation in the prognosis of patients with advanced melanoma, driven primarily by the advent of immune checkpoint inhibitors and targeted therapies. Agents that block programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have extended median overall survival from under one year to beyond two years in many clinical settings. Concurrently, BRAF and MEK inhibitors have offered rapid tumour control in patients harbouring actionable mutations, with combination regimens further enhancing durability of response. Real-world evidence confirms these gains, though outcomes vary according to patient age, performance status and presence of brain metastases. A growing proportion of individuals now achieve long-term remission or durable disease stabilisation, redefining advanced melanoma as a potentially chronic condition. Nevertheless, challenges remain in extending benefits to populations excluded from trials, in mitigating immune-related toxicity and in overcoming resistance mechanisms. Integrating biomarker-driven selection, optimising sequencing of therapies and widening access across health-care systems are pivotal to sustaining global improvements in survival.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Survival Outcomes in Advanced Melanoma Treatment publication trend
The graph below shows the total number of articles in survival outcomes in advanced melanoma treatment across all publications each year (not limited to Nature Index journals).
Technical terms
Overall Survival (OS): The duration from treatment initiation to death from any cause, a principal measure of therapeutic benefit.
Progression-Free Survival (PFS): The interval during which a patient’s disease does not worsen, often used to gauge early treatment efficacy.
Immune Checkpoint Inhibitor (ICI): A class of drugs that blocks proteins such as PD-1 or CTLA-4 to restore antitumour immunity.
BRAF/MEK Inhibitors: Targeted agents that interrupt signalling in melanoma cells harbouring BRAF mutations, frequently used in combination for improved response.
References
- Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021. EClinicalMedicine (2024).
- Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies. European Journal of Cancer (2023).
- From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway. Acta Oncologica (2024).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.